Skip to content
10-Q

Quarterly Report

Xenon Pharmaceuticals Inc. XENE

0001193125-26-212153

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 96.67M sh
Shares Diluted Q1 2026 · Mar 31, 2026 87.35M sh
Shares Diluted Q1 2026 · Mar 31, 2025 78.69M sh
Capex Q1 2026 · Mar 31, 2026 $133K
Capex Q1 2026 · Mar 31, 2025 $43K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$88.9M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$61.65M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $545.87M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $199.16M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.34B
Stockholders Equity Q1 2026 · Dec 31, 2025 $581.76M
Stockholders Equity Q1 2026 · Mar 31, 2025 $703.96M
Stockholders Equity Q1 2026 · Dec 31, 2024 $754.9M
Current Liabilities Q1 2026 · Mar 31, 2026 $39.82M
Current Liabilities Q1 2026 · Dec 31, 2025 $41.79M
Total Liabilities Q1 2026 · Mar 31, 2026 $48.99M
Total Liabilities Q1 2026 · Dec 31, 2025 $51.4M
Current Assets Q1 2026 · Mar 31, 2026 $1.11B
Current Assets Q1 2026 · Dec 31, 2025 $560.65M
Total Assets Q1 2026 · Mar 31, 2026 $1.39B
Total Assets Q1 2026 · Dec 31, 2025 $633.16M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.17
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.83
Eps Basic Q1 2026 · Mar 31, 2026 −$1.17
Eps Basic Q1 2026 · Mar 31, 2025 −$0.83
Sga Expense Q1 2026 · Mar 31, 2026 $23.82M
Sga Expense Q1 2026 · Mar 31, 2025 $19.04M
Rd Expense Q1 2026 · Mar 31, 2026 $88.51M
Rd Expense Q1 2026 · Mar 31, 2025 $61.2M
Net Income Q1 2026 · Mar 31, 2026 −$102.3M
Net Income Q1 2026 · Mar 31, 2025 −$65.05M
Operating Income Q1 2026 · Mar 31, 2026 −$112.33M
Operating Income Q1 2026 · Mar 31, 2025 −$72.74M